BioSpace News Archive

Mycovia Pharmaceuticals today announced the appointment of Tiffany Ahlers as Senior Vice President, Commercialization

RaySearch has been developing world-class software since 2000, at first selling advanced calculation modules to other vendors.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on Wednesday, August 7, 2019, before the opening of the U.S. financial markets.

Benitec Biopharma, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, announced its Appendix 4C for the quarter ending 31 July 2019.

This distinguished award recognizes those who have made an impact in the lives of patients with cancer

OTraces, Inc., a molecular diagnostics company specializing in early cancer detection, has announced completion of a preliminary study for detection of pancreatic cancer

This week Briye™ announced Debbie Landers as their new chief executive officer. The promotion from her previous role as President and COO positions Landers as the first female CEO in the company’s history.

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware, on behalf of NIIMBL, has entered into a Collaborative Research and Development Agreement (CRADA) with the Food and Drug Administration (FDA).

The National Organization for Rare Disorders®, the leading independent nonprofit organization representing the over 25 million Americans with rare diseases, has announced the Patient/Caregiver Opening Address speakers for the 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit, to be held October 21-22 in Washington, DC.

Axcella Health, (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions using novel compositions of endogenous metabolic modulators to address dysregulated metabolism and support health, announced the publication of data describing the safety, tolerability and impact of investigational product AXA2678 on short-term muscle disuse atrophy in young healthy men.